<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348058</url>
  </required_header>
  <id_info>
    <org_study_id>ColoPhone</org_study_id>
    <nct_id>NCT04348058</nct_id>
  </id_info>
  <brief_title>Telephone Services for Participation in Colorectal Cancer Screening</brief_title>
  <acronym>ColoPhone</acronym>
  <official_title>Telephone Services for Participation Improvement in Colorectal Cancer Screening: a Randomized Health Services Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Screening up, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre randomized health services study within the population-based primary
      colonoscopy screening program (PCSP) in Poland. Individuals, aged 55-60 years, willl be
      randomized in a 1:1:1 ratio to arms: (1) Invitation by post, (2) Call Center or (2) Combined
      invitation methods. The primary outcome measure is rate of participation in screening
      colonoscopy. The sample size of 6 300 participants will detect 3 to 5 percentage point
      differences (depending on the arms comparison) in participation rate between groups with 80%
      power and significance level 0.05, using Ochran-Mantel-Haenszel test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized health services study will be performed within national population-based
      screening program (PCSP) in Poland, including its population, infrastructure and database
      system.

      Individuals aged 55-64 years old, included in PCSP willl be randomly assigned (in 1:1:1
      ratio, stratified by gender, age, place of residence) to study arms and invited to screening
      colonoscopy to local PSCP centers.

      Invitation process by post in Control group (1) and partially in Combined group (3) - will be
      performed by coordinating PCSP center (practice as usual).

      Recruitment by telephone conversation in Call Center group (2) and partially in Combined
      group (3) - will be performed by Screening Up call center company. Colonoscopies will be
      performed in 6 selected PCSP centers.

      The sample size of 2,100 participants per group (350 participants from each group in each
      center, assuming 5% drop out and access to telephone numbers of 30% participants in relevant
      arms; calculation is based on a 95% confidence interval +/- 5% error probability) was
      calculated to detect a difference in participation rate of 15% in control group (based on
      PCSP participation rate in 2019) vs. 18.7% in Call Center group vs 25% in Combined Invitation
      group (0.025 significance level with 80% power). The difference was calculated for the
      Cochran-Mantel-Haenszel test, assuming that the initial reporting in the control group will
      be as high as it was in 2019.

      Differences in participation rate to screening colonoscopy between the study groups and the
      control group will be performed using Ochran-Mantel-Haenszel test (two-sided analysis),
      taking into account initial differences between rates at the significance level of 0.05.

      The Principal Investigator of the study asked the Bioethical Committee with a request to
      release participants from signing of informed consent form to participation in the study, as
      they take part in a nationwide PSCP, financed by Ministry of Health in Poland - the study
      character is the Randomized Health Services Study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>prospective</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participation rate to screening colonoscopy within PCSP per recruitment strategy</measure>
    <time_frame>26 weeks after intervention</time_frame>
    <description>The percentage of study participants who underwent screening colonoscopy relative to all PCSP participants to whom the invitation was sent in a given group during the observation period (intention-to-screen analysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate to invitation to screening colonoscopy</measure>
    <time_frame>26 weeks after intervention</time_frame>
    <description>Contact with local PCSP center</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6300</enrollment>
  <condition>Participation Rate, Patient</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Invitation letter and reminder letter to screening colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Call Center</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telephone recruitment by motivational conversation and colonoscopy appointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non responders to invitation and reminder letter will be recruited by telephone conversation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone recruitment to screening colonoscopy</intervention_name>
    <description>Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation</description>
    <arm_group_label>Call Center</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Combined methods recruitment to screening colonoscopy</intervention_name>
    <description>Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation</description>
    <arm_group_label>Combined</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  population included to invitation within Polish population based Colorectal cancer
             Screening Program (PCSP)

               -  55-64 of age

               -  no history of CRC

               -  no history of screening colonoscopy within PCSP

          -  adress of residence near (not further than 40 kilometers) local PCSP centers (selected
             for the study based on population density)

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marek Bugajski, PhD</last_name>
    <phone>+48 22 546 23 28</phone>
    <email>marek.bugajski@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Małgorzata Pisera</last_name>
    <phone>+48 22 546 23 28</phone>
    <email>mpisera@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Maria Sklodowska-Curie National Research Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <state>Mazovian</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marek Bugajski, PhD</last_name>
      <phone>+48 22 546 2328</phone>
      <email>marek.bugajski@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Małgorzata Pisera</last_name>
      <phone>+48 22 546 23 28</phone>
      <email>mpisera@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.</citation>
    <PMID>23485231</PMID>
  </reference>
  <reference>
    <citation>European Colorectal Cancer Screening Guidelines Working Group, von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, Steele RJ, Vieth M, Aabakken L, Altenhofen L, Ancelle-Park R, Antoljak N, Anttila A, Armaroli P, Arrossi S, Austoker J, Banzi R, Bellisario C, Blom J, Brenner H, Bretthauer M, Camargo Cancela M, Costamagna G, Cuzick J, Dai M, Daniel J, Dekker E, Delicata N, Ducarroz S, Erfkamp H, Espinàs JA, Faivre J, Faulds Wood L, Flugelman A, Frkovic-Grazio S, Geller B, Giordano L, Grazzini G, Green J, Hamashima C, Herrmann C, Hewitson P, Hoff G, Holten I, Jover R, Kaminski MF, Kuipers EJ, Kurtinaitis J, Lambert R, Launoy G, Lee W, Leicester R, Leja M, Lieberman D, Lignini T, Lucas E, Lynge E, Mádai S, Marinho J, Maučec Zakotnik J, Minoli G, Monk C, Morais A, Muwonge R, Nadel M, Neamtiu L, Peris Tuser M, Pignone M, Pox C, Primic-Zakelj M, Psaila J, Rabeneck L, Ransohoff D, Rasmussen M, Regula J, Ren J, Rennert G, Rey J, Riddell RH, Risio M, Rodrigues V, Saito H, Sauvaget C, Scharpantgen A, Schmiegel W, Senore C, Siddiqi M, Sighoko D, Smith R, Smith S, Suchanek S, Suonio E, Tong W, Törnberg S, Van Cutsem E, Vignatelli L, Villain P, Voti L, Watanabe H, Watson J, Winawer S, Young G, Zaksas V, Zappa M, Valori R. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45(1):51-9. doi: 10.1055/s-0032-1325997. Epub 2012 Dec 4.</citation>
    <PMID>23212726</PMID>
  </reference>
  <reference>
    <citation>Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson DJ. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017 Jul;153(1):307-323. doi: 10.1053/j.gastro.2017.05.013. Epub 2017 Jun 9.</citation>
    <PMID>28600072</PMID>
  </reference>
  <reference>
    <citation>Kaminski MF, Kraszewska E, Rupinski M, Laskowska M, Wieszczy P, Regula J. Design of the Polish Colonoscopy Screening Program: a randomized health services study. Endoscopy. 2015 Dec;47(12):1144-50. doi: 10.1055/s-0034-1392769. Epub 2015 Oct 30.</citation>
    <PMID>26517847</PMID>
  </reference>
  <reference>
    <citation>Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P, Guasticchi G, Giorgi Rossi P; Methods to increase participation Working Group. Methods to increase participation in organised screening programs: a systematic review. BMC Public Health. 2013 May 13;13:464. doi: 10.1186/1471-2458-13-464. Review.</citation>
    <PMID>23663511</PMID>
  </reference>
  <reference>
    <citation>Goodwin BC, Ireland MJ, March S, Myers L, Crawford-Williams F, Chambers SK, Aitken JF, Dunn J. Strategies for increasing participation in mail-out colorectal cancer screening programs: a systematic review and meta-analysis. Syst Rev. 2019 Nov 4;8(1):257. doi: 10.1186/s13643-019-1170-x.</citation>
    <PMID>31685010</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maria Sklodowska-Curie Institute - Oncology Center</investigator_affiliation>
    <investigator_full_name>Marek Bugajski</investigator_full_name>
    <investigator_title>PhD, MD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer screening</keyword>
  <keyword>screening colonoscopy</keyword>
  <keyword>screening participation</keyword>
  <keyword>telephone services</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

